Provided by Tiger Trade Technology Pte. Ltd.

Immunic, Inc.

0.9125
+0.04244.87%
Post-market: 0.92450.0120+1.32%19:59 EST
Volume:64.41M
Turnover:69.83M
Market Cap:109.76M
PE:-1.09
High:1.20
Open:1.13
Low:0.9100
Close:0.8701
52wk High:1.39
52wk Low:0.5062
Shares:120.28M
Float Shares:95.79M
Volume Ratio:16.82
T/O Rate:67.24%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8362
EPS(LYR):-1.0033
ROE:-398.50%
ROA:-125.08%
PB:10.45
PE(LYR):-0.91

Loading ...

Why Is Immunic Stock Soaring Friday?

Benzinga
·
Feb 14

BUZZ-U.S. STOCKS ON THE MOVE-Moderna, Mohawk,

Reuters
·
Feb 14

Why Is Immunic Stock (IMUX) Up 27% Today?

TIPRANKS
·
Feb 13

BUZZ-U.S. STOCKS ON THE MOVE-Opus Genetics, MetaVia, Enbridge

Reuters
·
Feb 13

Immunic Shares Climb After Private Placement Is Priced

Dow Jones
·
Feb 13

Immunic Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Feb 13

Shares of Immunic up 21.8% Premarket After Co Raises $400 Mln for Multiple Sclerosis Drug Trials

THOMSON REUTERS
·
Feb 13

BUZZ-Immunic jumps as biotech raises up to $400 million for MS drug trials

Reuters
·
Feb 13

Immunic Announces Oversubscribed Private Placement Of Up To USD 400 Million To Accelerate Transformation Into Commercial-Stage Company

Reuters
·
Feb 13

Immunic Announces Issuance of Warrants to Raise Up to $200 Million

Reuters
·
Feb 13

Eqs-News: Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation Into Commercial-Stage Company

THOMSON REUTERS
·
Feb 13

Immunic Inc - Co-Founder and Chief Executive Officer Daniel Vitt and Board of Directors Will Begin a Search for a New CEO

THOMSON REUTERS
·
Feb 13

Immunic Inc: Proceeds of Financing Expected to Support Co's Transition From Research & Development-Focused Co Into Fully Integrated Commercial Entity

THOMSON REUTERS
·
Feb 13

Press Release: Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company

Dow Jones
·
Feb 13

Immunic Price Target Maintained With a $8.00/Share by HC Wainwright & Co.

Dow Jones
·
Feb 09

Immunic Unveils Positive Phase 2 CALLIPER Trial Data for Vidofludimus Calcium in Progressive Multiple Sclerosis

Reuters
·
Feb 04

Eqs-News: Immunic to Present Additional Phase 2 Calliper Trial Data for Vidofludimus Calcium at the Actrims Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis

THOMSON REUTERS
·
Feb 04

Insider Traders Lose US$42k As Immunic Drops

Simply Wall St.
·
Jan 30

Immunic Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Jan 07

Immunic Inc. Faces Nasdaq Delisting Risk Over Continued Low Share Price

Reuters
·
Jan 07